Moreover, in a phase II clinical trial, Telaglenastat (CB-839), a selective GLS1 inhibitor, in combination with Everolimus, demonstrated promising therapeutic effects in patients with RCC [62]. The gene discussed is GLS; the disease is renal cell carcinoma.